The minimal residual disease testing market size has grown rapidly in recent years. It will grow from $1.59 billion in 2024 to $1.81 billion in 2025 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to advancements in cancer research, treatment monitoring needs, clinical evidence, regulatory support, patient outcome improvement.
The minimal residual disease testing market size is expected to see rapid growth in the next few years. It will grow to $2.96 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to increasing cancer incidence, therapeutic advancements, precision medicine trends, shift toward early detection, healthcare system integration. Major trends in the forecast period include integration of liquid biopsy approaches, focus on early detection of relapse, expansion of MRD testing in clinical trials, increasing adoption in pediatric oncology, collaborations for research and development.
The anticipated increase in cancer cases is set to drive the growth of the minimal residual disease testing market. Cancer, characterized by uncontrolled cell growth and spread in the body, is primarily diagnosed and monitored through minimal residual disease testing - a highly sensitive method detecting residual cancer cells. This testing aids in the early-stage prevention of cancer, contributing to the expansion of the minimal residual disease testing market. For example, the American Cancer Society Inc. reported an estimated 1.9 million new cancer cases and 609,360 cancer-related deaths in the United States in 2022, emphasizing the critical role of minimal residual disease testing in managing cancer.
The growing demand for personalized medicine is expected to propel the minimal residual disease testing market. Personalized medicine tailors healthcare interventions based on individual characteristics such as genetics, lifestyle, and environment, optimizing treatments for better outcomes. Minimal residual disease testing is crucial in this context, precisely monitoring residual cancer cells post-treatment to facilitate targeted therapies. In 2022, the Food and Drug Administration’s Center for Drug Evaluation and Research approved 37 new molecular entities, and approximately 34% of therapeutic NMEs, equivalent to 12, were classified as personalized medicines by the Personalized Medicine Coalition. This highlights the increasing demand for personalized medicine and its positive impact on the growth of the minimal residual disease testing market.
Product innovation emerges as a prominent trend in the minimal residual disease testing market, with major companies introducing new solutions to maintain their market positions. Twist Bioscience, a US-based synthetic biology and genomics company, launched the Twist MRD Panel in 2022, aiming to advance research and development in minimal residual disease detection in cancer screening. This customizable panel of genes is designed to detect very low levels of residual cancer cells in a patient's blood, offering flexibility and integration into next-generation sequencing workflows.
Major companies in the minimal residual disease testing market are also focusing on cancer research testing solutions to enhance detection sensitivity, improve treatment monitoring, and advance precision medicine approaches. For instance, Integrated DNA Technologies (IDT), a US-based genomic solutions provider, introduced the IDT Archer FUSIONPlex Core Solid Tumor Panel in April 2023. This enhanced cancer research testing solution simplifies fusion detection and variant calling in solid tumors, providing researchers with a scalable, user-friendly solution that saves time and resources.
In April 2023, Quest Diagnostics, a U.S.-based clinical laboratory, acquired Haystack Oncology. This acquisition aims to enhance personalized cancer care through Haystack's liquid biopsy technology, which detects residual or recurring cancer by identifying circulating tumor DNA (ctDNA) in the bloodstream. This method prioritizes early and accurate detection of cancer recurrence, aiding in treatment decisions and improving patient outcomes. Ultimately, this technology facilitates more effective management of cancer treatment. Haystack Oncology, Inc. is a U.S.-based biotechnology company.
Major companies operating in the minimal residual disease testing market include Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton, Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Janssen Diagnostics LLC, Luminex Corporation, Menarini Silicon Biosystems S.p.A.
North America was the largest region in the minimal residual disease testing market in 2024. The regions covered in the minimal residual disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the minimal residual disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Minimal residual disease testing involves highly sensitive tests aimed at detecting cancer cells that may persist in a patient's body after treatment. This type of testing is crucial for monitoring the effectiveness of cancer treatment and guiding future treatment strategies.
The main types of tests for minimal residual disease testing include DNA-based tests, RNA-based tests, and immunological tests. DNA-based testing, also known as genetic testing, is a medical examination designed to identify changes in chromosomes, genes, or proteins. Various technologies, such as flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others, are employed in applications such as hematological malignancies, leukemia, lymphoma, solid tumors, and more. These tests are utilized by hospitals and specialty clinics, diagnostic laboratories, academic and research institutes, and other healthcare entities.
The minimal residual disease testing market research report is one of a series of new reports that provides minimal residual disease testing market statistics, including minimal residual disease testing industry global market size, regional shares, competitors with a minimal residual disease testing market share, detailed minimal residual disease testing market segments, market trends and opportunities, and any further data you may need to thrive in the minimal residual disease testing industry. This minimal residual disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The minimal residual disease testing market includes revenues earned by entities by providing services such as peripheral blood cell testing, sequencing testing, high-throughput sequencing testing, and methylation sequencing testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The minimal residual disease testing market size is expected to see rapid growth in the next few years. It will grow to $2.96 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to increasing cancer incidence, therapeutic advancements, precision medicine trends, shift toward early detection, healthcare system integration. Major trends in the forecast period include integration of liquid biopsy approaches, focus on early detection of relapse, expansion of MRD testing in clinical trials, increasing adoption in pediatric oncology, collaborations for research and development.
The anticipated increase in cancer cases is set to drive the growth of the minimal residual disease testing market. Cancer, characterized by uncontrolled cell growth and spread in the body, is primarily diagnosed and monitored through minimal residual disease testing - a highly sensitive method detecting residual cancer cells. This testing aids in the early-stage prevention of cancer, contributing to the expansion of the minimal residual disease testing market. For example, the American Cancer Society Inc. reported an estimated 1.9 million new cancer cases and 609,360 cancer-related deaths in the United States in 2022, emphasizing the critical role of minimal residual disease testing in managing cancer.
The growing demand for personalized medicine is expected to propel the minimal residual disease testing market. Personalized medicine tailors healthcare interventions based on individual characteristics such as genetics, lifestyle, and environment, optimizing treatments for better outcomes. Minimal residual disease testing is crucial in this context, precisely monitoring residual cancer cells post-treatment to facilitate targeted therapies. In 2022, the Food and Drug Administration’s Center for Drug Evaluation and Research approved 37 new molecular entities, and approximately 34% of therapeutic NMEs, equivalent to 12, were classified as personalized medicines by the Personalized Medicine Coalition. This highlights the increasing demand for personalized medicine and its positive impact on the growth of the minimal residual disease testing market.
Product innovation emerges as a prominent trend in the minimal residual disease testing market, with major companies introducing new solutions to maintain their market positions. Twist Bioscience, a US-based synthetic biology and genomics company, launched the Twist MRD Panel in 2022, aiming to advance research and development in minimal residual disease detection in cancer screening. This customizable panel of genes is designed to detect very low levels of residual cancer cells in a patient's blood, offering flexibility and integration into next-generation sequencing workflows.
Major companies in the minimal residual disease testing market are also focusing on cancer research testing solutions to enhance detection sensitivity, improve treatment monitoring, and advance precision medicine approaches. For instance, Integrated DNA Technologies (IDT), a US-based genomic solutions provider, introduced the IDT Archer FUSIONPlex Core Solid Tumor Panel in April 2023. This enhanced cancer research testing solution simplifies fusion detection and variant calling in solid tumors, providing researchers with a scalable, user-friendly solution that saves time and resources.
In April 2023, Quest Diagnostics, a U.S.-based clinical laboratory, acquired Haystack Oncology. This acquisition aims to enhance personalized cancer care through Haystack's liquid biopsy technology, which detects residual or recurring cancer by identifying circulating tumor DNA (ctDNA) in the bloodstream. This method prioritizes early and accurate detection of cancer recurrence, aiding in treatment decisions and improving patient outcomes. Ultimately, this technology facilitates more effective management of cancer treatment. Haystack Oncology, Inc. is a U.S.-based biotechnology company.
Major companies operating in the minimal residual disease testing market include Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton, Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Janssen Diagnostics LLC, Luminex Corporation, Menarini Silicon Biosystems S.p.A.
North America was the largest region in the minimal residual disease testing market in 2024. The regions covered in the minimal residual disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the minimal residual disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Minimal residual disease testing involves highly sensitive tests aimed at detecting cancer cells that may persist in a patient's body after treatment. This type of testing is crucial for monitoring the effectiveness of cancer treatment and guiding future treatment strategies.
The main types of tests for minimal residual disease testing include DNA-based tests, RNA-based tests, and immunological tests. DNA-based testing, also known as genetic testing, is a medical examination designed to identify changes in chromosomes, genes, or proteins. Various technologies, such as flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others, are employed in applications such as hematological malignancies, leukemia, lymphoma, solid tumors, and more. These tests are utilized by hospitals and specialty clinics, diagnostic laboratories, academic and research institutes, and other healthcare entities.
The minimal residual disease testing market research report is one of a series of new reports that provides minimal residual disease testing market statistics, including minimal residual disease testing industry global market size, regional shares, competitors with a minimal residual disease testing market share, detailed minimal residual disease testing market segments, market trends and opportunities, and any further data you may need to thrive in the minimal residual disease testing industry. This minimal residual disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The minimal residual disease testing market includes revenues earned by entities by providing services such as peripheral blood cell testing, sequencing testing, high-throughput sequencing testing, and methylation sequencing testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Minimal Residual Disease Testing Market Characteristics3. Minimal Residual Disease Testing Market Trends and Strategies4. Minimal Residual Disease Testing Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Minimal Residual Disease Testing Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Minimal Residual Disease Testing Market34. Recent Developments in the Minimal Residual Disease Testing Market
5. Global Minimal Residual Disease Testing Growth Analysis and Strategic Analysis Framework
6. Minimal Residual Disease Testing Market Segmentation
7. Minimal Residual Disease Testing Market Regional and Country Analysis
8. Asia-Pacific Minimal Residual Disease Testing Market
9. China Minimal Residual Disease Testing Market
10. India Minimal Residual Disease Testing Market
11. Japan Minimal Residual Disease Testing Market
12. Australia Minimal Residual Disease Testing Market
13. Indonesia Minimal Residual Disease Testing Market
14. South Korea Minimal Residual Disease Testing Market
15. Western Europe Minimal Residual Disease Testing Market
16. UK Minimal Residual Disease Testing Market
17. Germany Minimal Residual Disease Testing Market
18. France Minimal Residual Disease Testing Market
19. Italy Minimal Residual Disease Testing Market
20. Spain Minimal Residual Disease Testing Market
21. Eastern Europe Minimal Residual Disease Testing Market
22. Russia Minimal Residual Disease Testing Market
23. North America Minimal Residual Disease Testing Market
24. USA Minimal Residual Disease Testing Market
25. Canada Minimal Residual Disease Testing Market
26. South America Minimal Residual Disease Testing Market
27. Brazil Minimal Residual Disease Testing Market
28. Middle East Minimal Residual Disease Testing Market
29. Africa Minimal Residual Disease Testing Market
30. Minimal Residual Disease Testing Market Competitive Landscape and Company Profiles
31. Minimal Residual Disease Testing Market Other Major and Innovative Companies
35. Minimal Residual Disease Testing Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Minimal Residual Disease Testing Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on minimal residual disease testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for minimal residual disease testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The minimal residual disease testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- the market characteristics section of the report defines and explains the market.
- the market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- the forecasts are made after considering the major factors currently impacting the market. These include:
- the forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- the regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- the competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- the trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Test Type: DNA - Based Test; RNA- Based Test; Immunological Test2) by Technology: Flow Cytometry; Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Other Technologies
3) by Application: Hematological Malignancies; Leukemia; Lymphoma; Solid Tumors; Other Application
4) by End User: Hospitals and Specialty Clinics; Diagnostic Laboratories; Academic and Research Institutes; Other End Users
Subsegments:
1) by DNA-Based Test: Polymerase Chain Reaction (PCR) Tests; Next-Generation Sequencing (NGS); Digital PCR2) by RNA-Based Test: Reverse Transcription PCR (RT-PCR); RNA Sequencing; Quantitative PCR (qPCR)
3) by Immunological Test: Flow Cytometry; Enzyme-Linked Immunosorbent Assay (ELISA); Immunohistochemistry
Key Companies Mentioned: Natera Inc.; Guardant Health Inc.; Laboratory Corporation of America Holdings; QIAGEN NV; F. Hoffmann-La Roche Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Minimal Residual Disease Testing market report include:- Natera Inc.
- Guardant Health Inc.
- Laboratory Corporation of America Holdings
- QIAGEN NV
- F. Hoffmann-La Roche Ltd.
- Bio-Techne Corporation
- Bio-Rad Laboratories Inc.
- Sysmex Corporation
- Exact Sciences Corporation
- GRAIL LLC
- Veracyte Inc.
- Cergentis B.V
- Mdxhealth SA
- NeoGenomics Laboratories Inc.
- Adaptive Biotechnologies
- OPKO Health Inc.
- Thermo Fisher Scientific Inc.
- Siemens Healthineers AG
- PerkinElmer Inc.
- Agilent Technologies Inc.
- ArcherDx Inc.
- Asuragen Inc.
- Becton, Dickinson and Company
- Cepheid Inc.
- Fluidigm Corporation
- Illumina Inc.
- Invitae Corporation
- Janssen Diagnostics LLC
- Luminex Corporation
- Menarini Silicon Biosystems S.p.A.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 1.81 Billion |
| Forecasted Market Value ( USD | $ 2.96 Billion |
| Compound Annual Growth Rate | 13.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
